Difference between revisions of "Team:Bordeaux/Description"
Line 160: | Line 160: | ||
<p align="justify" style="text-indent: 3vw;"> Curdlan has also found applications in non-food sectors. Its water-holding capacity is applied in the formulation of “superworkable” concrete, where its enhanced fluidity prevents cement and small stones from segregating [8]. It has also been proposed as an organic binding agent for ceramics [9]. In addition, curdlan gels have medical and pharmacological potential, for example in drug delivery through sustained and diffusion-controlled release of the active ingredient. [10]</p> | <p align="justify" style="text-indent: 3vw;"> Curdlan has also found applications in non-food sectors. Its water-holding capacity is applied in the formulation of “superworkable” concrete, where its enhanced fluidity prevents cement and small stones from segregating [8]. It has also been proposed as an organic binding agent for ceramics [9]. In addition, curdlan gels have medical and pharmacological potential, for example in drug delivery through sustained and diffusion-controlled release of the active ingredient. [10]</p> | ||
− | <p align="justify" style="text-indent: 3vw;"> Furthermore, curdlan derivatives are members of a class of compounds known as biological response modifiers that enhance or restore normal immune defences. Useful properties include antitumor, anti-infective, anti-inflammatory, and anticoagulant activities [11] Hydrolysed curdlans with a degree of polymerisation <50 are not effective anti-tumour agents but the carboxymethyl ether and the sulphate and phosphate esters of curdlan, show an enhanced biological activity [12]. Furthermore, curdlan sulphate has anti-HIV activity [13] and inhibitory effects on the development of malarial parasites in vitro [14]. All the other curdlan clinical applications in cancer, diabetes, hypertension, hypertriglyceridemia etc. are listed <a href ="https://static.igem.org/mediawiki/2015/f/fb/Bordeaux_Clinical_Applications.pdf"> here</a>. Curdlan also has potential for exploitation as a new biomaterial based on the self-assembling ability of (1→3)-β-glucan-megalosaccharides (DP 30–45) to form single, hexagonal, lamellar nanocrystalline structures (∼8–9 nm thick) containing water of crystallization after heating to 90°C | + | <p align="justify" style="text-indent: 3vw;"> Furthermore, curdlan derivatives are members of a class of compounds known as biological response modifiers that enhance or restore normal immune defences. Useful properties include antitumor, anti-infective, anti-inflammatory, and anticoagulant activities [11] Hydrolysed curdlans with a degree of polymerisation <50 are not effective anti-tumour agents but the carboxymethyl ether and the sulphate and phosphate esters of curdlan, show an enhanced biological activity [12]. Furthermore, curdlan sulphate has anti-HIV activity [13] and inhibitory effects on the development of malarial parasites in vitro [14]. All the other curdlan clinical applications in cancer, diabetes, hypertension, hypertriglyceridemia etc. are listed <a href ="https://static.igem.org/mediawiki/2015/f/fb/Bordeaux_Clinical_Applications.pdf"> here</a>. Curdlan also has potential for exploitation as a new biomaterial based on the self-assembling ability of (1→3)-β-glucan-megalosaccharides (DP 30–45) to form single, hexagonal, lamellar nanocrystalline structures (∼8–9 nm thick) containing water of crystallization after heating to 90°C [15]. Manipulation of the conditions for self-assembly may allow the engineering of new materials. </p> |
<p align="justify" style="text-indent: 3vw;"> The full potential of curdlan in existing and proposed applications would be enhanced by reducing the cost of production. This may involve the use of cheaper C sources, optimisation of fermentation conditions, development of higher curdlan-yielding strains, or manipulation of curdlan synthesis and/or regulatory genes. </p> | <p align="justify" style="text-indent: 3vw;"> The full potential of curdlan in existing and proposed applications would be enhanced by reducing the cost of production. This may involve the use of cheaper C sources, optimisation of fermentation conditions, development of higher curdlan-yielding strains, or manipulation of curdlan synthesis and/or regulatory genes. </p> | ||
Line 181: | Line 181: | ||
<p class="reference" align="left"> [13] Jagodzinski PP, Wiaderkiewicz R (1994) Mechanism of the inhibitory effect of curdlan sulphate on HIV-1 infection in vitro. Virology 202:735–745 </p> | <p class="reference" align="left"> [13] Jagodzinski PP, Wiaderkiewicz R (1994) Mechanism of the inhibitory effect of curdlan sulphate on HIV-1 infection in vitro. Virology 202:735–745 </p> | ||
<p class="reference" align="left"> [14] Evans SG, Morrison D, Kaneko Y, Havlik I (1998) The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans R Soc Trop Med Hyg 92:87–89 </p> | <p class="reference" align="left"> [14] Evans SG, Morrison D, Kaneko Y, Havlik I (1998) The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans R Soc Trop Med Hyg 92:87–89 </p> | ||
− | + | <p class="reference" align="left"> [15]Chanzy H, Vuong R (1985) Ultrastructure and morphology of crystalline polysaccharides. In Atkins EDT (ed) Polysaccharides: topics in structure and morphology. Macmillan, London, pp 41–71 </p> | |
Revision as of 08:24, 15 August 2015